Synergistic effects of olaparib combined with < em > ERCC1 < /em > on the sensitivity of cisplatin in non-small cell lung cancer

In conclusion, olaparib combined with ERCC1 expression may enhance the sensitivity of cisplatin in NSCLC. These findings may provide novel insight for the improvement of platinum drug sensitivity and treatment of NSCLC.PMID:33747222 | PMC:PMC7967929 | DOI:10.3892/ol.2021.12626
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research